Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2014 Nov;64(5):770-80. doi: 10.1053/j.ajkd.2014.04.014. Epub 2014 May 13.

Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.

Author information

  • 1Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN; University of Minnesota, College of Pharmacy, Minneapolis, MN.
  • 2Center for Medicare and Medicaid Innovation, Centers for Medicare & Medicaid Services, Baltimore, MD.
  • 3Center for Strategic Planning, Centers for Medicare & Medicaid Services, Baltimore, MD.
  • 4Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN; University of Minnesota, College of Pharmacy, Minneapolis, MN. Electronic address: wstpeter@cdrg.org.

Abstract

BACKGROUND:

Information is limited regarding utilization patterns and costs for chronic kidney disease-mineral and bone disorder (CKD-MBD) medications in Medicare Part D-enrolled dialysis patients.

STUDY DESIGN:

Retrospective cohort study.

SETTING & PARTICIPANTS:

Annual cohorts of dialysis patients, 2007-2010.

PREDICTORS:

Cohort year, low-income subsidy status, and dialysis provider.

OUTCOMES:

Utilization and costs of prescription phosphate binders, oral and intravenous vitamin D analogues, and cinacalcet.

MEASUREMENTS:

Using logistic regression, we calculated adjusted odds of medication use for low-income subsidy versus non-low-income subsidy patients and for patients from various dialysis organizations, and we report per-member-per-month and average out-of-pocket costs.

RESULTS:

Phosphate binders (∼83%) and intravenous vitamin D (77.5%-79.3%) were the most commonly used CKD-MBD medications in 2007 through 2010. The adjusted odds of prescription phosphate-binder, intravenous vitamin D, and cinacalcet use were significantly higher for low-income subsidy than for non-low-income subsidy patients. Total Part D versus CKD-MBD Part D medication costs increased 22% versus 36% from 2007 to 2010. For Part D-enrolled dialysis patients, CKD-MBD medications represented ∼50% of overall net Part D costs in 2010.

LIMITATIONS:

Inability to describe utilization and costs of calcium carbonate, an over-the-counter agent not covered under Medicare Part D; inability to reliably identify prescriptions filled through a non-Part D reimbursement or payment mechanism; findings may not apply to dialysis patients without Medicare Part D benefits or with Medicare Advantage plans, or to pediatric dialysis patients; could identify only prescription drugs dispensed in the outpatient setting; inability to adjust for MBD laboratory values.

CONCLUSIONS:

Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.

Copyright © 2014 National Kidney Foundation, Inc. All rights reserved.

KEYWORDS:

Chronic kidney disease (CKD); Medicare Part D; calcimimetics; dialysis; medication costs; mineral and bone disorder; phosphate binders; vitamin D analogues

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk